Cholangiocarcinoma (CCA) is one of the most aggressive tumors of the hepatobiliary system and is often only diagnosed at an advanced stage. Advances in molecular diagnostics and targeted therapy are increasingly opening up personalized treatment options.
Autoren
- Dr. oec. Odile Schwarz-Herion
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
- approved FGFR inhibitors pemigatinib and futibatinib
- BRAF-V600E
- Cholangiocarcinoma
- Clinical studies Cholangiocarcinoma
- Combination of dabrafenib and trametinib
- Dabrafenib Trametinib
- dMMR
- Entrectinib
- extrahepatic cholangiocarcinoma
- FGFR inhibitors
- FGFR2 fusion
- FIGHT-202 study
- FOENIX-CCA2 study
- Futibatinib
- HER2 amplification
- HER2-positive extrahepatic CCA
- HER2-targeted therapy
- IDH1 mutation
- intrahepatic cholangiocarcinoma
- Ivosidenib effective second-line therapy
- Larotrectinib
- molecular alterations
- molecular diagnostics
- MSI-H
- Next-generation sequencing
- NGS profiling
- NTRK merger
- NTRK mergers
- Pembrolizumab
- Pemigatinib in previously treated patients with FGFR2 fusions
- Personalized oncology
- Prognosis and therapy
- Targeted therapy
- Trastuzumab-based combinations
- TRK Inhibitors
- Tumor Board Switzerland
- tumor-agnostic therapies such as larotrectinib or entrectinib
- Tumors with BRAF V600E mutations
You May Also Like
- Focus Update 2026
Echocardiography in Cardio-Oncology
- Physical activity with IBD
Sport is not murder, but it doesn’t help either
- White and Black Skin Cancer
Biology and Modern Therapeutic Approaches
- Highlights from the AAD Annual Meeting
Atopic Dermatitis: Interesting News on Drug Candidates in Phase III
- Autoimmune Liver Diseases
Innovative Treatment Approaches for PBC, PSC, and AIH: What’s New?
- Myelofibrosis
Mutations and Molecular Diagnostics in Treatment Decisions
- Psoriasis in the Age of Precision Medicine
Systemic Therapy for Patients with Comorbidities: What Is the Best Choice?
- The AMALFI study and the limits of digital screening for atrial fibrillation